With all the attention the top-performing health care sector, and biopharmaceutical stocks in particular, are receiving, which biotech stocks are worth a look ahead of their first-quarter earnings reports? Analysts at Goldman Sachs have identified four that they are bullish on, and today’s article notes that “While their shares only suited for aggressive growth accounts with a high-risk profile, none of these companies is a proverbial one-trick pony. In addition, they all are potential takeover candidates.” For more, CLICK HERE.
Ahead Of Q1 Earnings, Goldman Sachs Is Bullish On These 4 Biotech Stocks
Tags:Biopharmaceutical StocksBiotech StocksBullish MarketEarnings ReportsGoldman SachsHigh-Risk ProfileInvestInvestingQ1 EarningsStock Market